cytochrome P450 family 2 subfamily G member 2, pseudogeneGenealiases: CYP2G2 · CYP2GP2
Q-omics provides the consensus-scored CYP2G2P profile across patient tissues and cancer cell-line models. CYP2G2P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CYP2G2P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, CYP2G2P RNA expression shows 6,764 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUSC, and STAD as cancer lineages where CYP2G2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2G2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2G2P survival associations across molecular data types. CYP2G2P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2G2P RNA expression–survival associations across cancer types. High CYP2G2P expression shows unfavorable associations in COAD, KIRC and DLBC, but favorable associations in BRCA, HNSC and PRAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for CYP2G2P RNA expression.
This table summarizes CYP2G2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2G2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2G2P shows lower tumor expression in LUSC and LUAD and higher tumor expression in PRAD. The LUSC box plot shows higher CYP2G2P RNA expression in normal versus tumor tissue (log2 FC = −0.108, t-test p = .026).
This table shows molecular features associated with CYP2G2P in patient tissues and cancer cell lines. In patient samples, CYP2G2P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
